The biotech industry faces a looming patent cliff in oncology as several blockbuster cancer drugs, including immunotherapies approved in the mid-2010s, approach loss of exclusivity within the next five years. Historical data from drugs like Avastin and Gleevec illustrate the dramatic revenue declines that accompany biosimilar and generic competition, often exceeding 40-50%. This places heavy pressure on pharmaceutical companies to implement proactive lifecycle management, diversify pipelines, or pursue strategic acquisitions to sustain valuation and market share. Drugs such as Keytruda, Opdivo, and Darzalex represent tens of billions in annual revenue at risk, underscoring the critical nature of current pipeline positioning for sponsors.